Skip to Content
Merck
CN

Key Documents

View All Documentation

S-008

Sufentanil Citrate solution

100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C22H30N2O2S · C6H8O7
CAS Number:
60561-17-3
Molecular Weight:
578.67
NACRES:
NA.24
PubChem Substance ID:
329824410
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
MFCD00072116
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal), kontrollierte Droge in Deutschland

concentration

100 μg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

-10 to -25°C

SMILES string

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCC(=O)N(c1ccccc1)C2(CCN(CCc3cccs3)CC2)COC

InChI

1S/C22H30N2O2S.C6H8O7/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,17H,3,11-16,18H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

InChI key

OJCZPLDERGDQRJ-UHFFFAOYSA-N

Gene Information

human ... OPRM1(4988)

General description

Sufentanil is a short acting synthetic opioid analgesic most commonly used for pain relief during medical operations. This certified solution standard is applicable to use in clinical toxicology, pain prescription monitoring, or forensic analysis by LC-MS/MS or GC/MS. Sufentanil is sold under the trade name Sufenta.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

监管及禁止进口产品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Fechner et al.
European journal of pain (London, England), 17(4), 562-570 (2012-08-29)
There is an ongoing debate whether opioids when used for intra-operative analgesia may enhance post-operative pain. We studied the effect of two different intra-operative dosings of sufentanil on post-operative morphine consumption, pain and hyperalgesia after cardiac anaesthesia. Forty-two male patients
Robert Stephen et al.
Journal of opioid management, 8(4), 237-241 (2012-09-04)
In emergency medicine, the ability to provide rapid, adequate pain control without high resource utilization is ideal. In this study, the efficacy of intranasal sufentanil in emergency department (ED) patients with acute distal extremity injury was evaluated. A nonrandomized, open-label
S Karason et al.
Acta anaesthesiologica Scandinavica, 57(5), 639-645 (2013-02-26)
Bladder catheterisation may be inconvenient for patients, delay mobilisation and risk complications. We hypothesised that by excluding pre-operatively patients at high risk of post-operative urinary retention, the majority of patients could avoid perioperative catheterisation during low-dose spinal anaesthesia. Patients undergoing
View All Related Papers

Global Trade Item Number

SKUGTIN
S-008-1ML04061836829247